More companies announce ASRS 2024 presentations
Companies continue to share news about the data that will be presented at the 2024 ASRS meeting in Stockholm, Sweden.
(Image credit: AdobeStock/kasto)
The retina community is busy as they prepare for one of its biggest meetings of the year, the annual American Society of Retina Specialists (ASRS) event. The 42nd Annual ASRS meeting will be held from July 17-20, 2024 in Stockholm, Sweden.
This meeting will connect retina specialists from around the country and the globe to discuss the latest research, discuss clinical trials, and network with one another. Companies also use this event to showcase new data and update the community on the progress of pharmaceutical candidates, surgical techniques, and practice management techniques.
As the meeting draws nearer, more companies announce the presentations related to their research. Below is a non-exhaustive list of companies and the information surrounding their ASRS presentations (in alphabetical order). Modern Retina will continue to highlight additional announcements as they are made.
Annexon Inc.
The company will have two oral presentations at the ASRS meeting. The first, by Glenn J. Jaffe, MD, entitled, "Protective Effects of ANX007 on Central Macular Ellipsoid Zone (EZ) and Retinal Pigment Epithelium (RPE) and Association with Visual Acuity in the Phase 2 ARCHER GA Study" will take place on July 18, at 8:42 am CEST.1
The second will be presented by Joel Pearlman, MD, PhD, and will be, "Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial." This will take place on July 18 at 1:36 pm CEST.1
Apellis Pharmaceuticals
Apellis has announced that data on the efficacy and safety of pegcetacoplan will be featured in several presentations at the ASRS meeting along with studies on geographic atrophy.2 These will include:
- Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months
- Presenter: Paul Hahn, MD, PhD, FASRS
- Wednesday, July 17, 9:30 am CEST
- Identification of Disease Activity and Therapeutic Response in Geographic Atrophy by Human Experts and OCT-Based AI Analysis in Pegcetacoplan Therapy
- Presenter: Ursula M Schmidt-Erfurth, MD
- Wednesday, July 17, 11:00 am CEST
- Predictive Role of Outer Retinal Tubulation in Lesion Growth for Subfoveal and Nonsubfoveal Geographic Atrophy
- Presenter: Srinivas Sai A Kondapalli, MD
- Thursday, July 18, 8:34 am CEST
- Update on Pegcetacoplan for Geographic Atrophy: Clinical Studies and Real-World Experience
- Presenter: David A Eichenbaum, MD, FASRS
- Thursday, July 18, 3:25 pm CEST
- Visual Function Benefit of Pegcetacoplan on a Prespecified Microperimetry Endpoint after 36 Months of Continuous Treatment from GALE
- Presenter: Sunir J Garg, MD, FACS, FASRS
- Thursday, July 18, 3:25 pm CEST
Nanoscope Therapeutics
A presentation, titled, “BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: FIRST TIME 100-week TOPLINE Results from a Phase 2b/3 Randomized Sham-Controlled Clinical Trial (RESTORE)” will be given by Michael Singer, MD on Friday, July 19, at 9:17 am CEST. This will cover the recently announced 100-week data from on the candidate MCO-010.3
Ocular Therapeutix
Ocular Therapeutix announced a late -breaking abstract on their HELIOS Phase 1 study will be presented by Dilsher S. Dhoot, MD. The presentation entitled, Interim Safety and Efficacy Results From the Phase 1 HELIOS Trial of Sustained-release Axitinib Implant (OTX-TKI) for NPDR,” will take place on July 18, 2024 at 10:47 am CEST.4
Ocuphire Pharma
The company will share a virtual paper-on-demand as part of the ASRS meeting. This presentation, given by Kareem Sioufi, MD, entitled “Effect of Oral APX3330 on Progression of Non-Proliferative Diabetic Retinopathy Utilizing a Binocular DRSS Person-Level Scale,” will be available to ASRS attendees beginning July 17, 2024 in the on-demand content library.5
